VisiDome

VisiDome is developing an accommodative IOL that offers clear, spectacle-free vision at all distances. 

The VisiDome Opportunity

Delivering true accommodative vision – the ability to change focus – to see up close, far away, and everything in between without glasses continues to be the ultimate goal.

The Product

VisiDome is developing an accommodative IOL that offers clear, spectacle-free vision at all distances. The Company’s innovative approach is its simple, effective design that efficiently exploits the eyes’ natural accommodating mechanism and overcomes existing flaws of premium lenses.

The VisiDome IOL is an add-on to standard monofocal IOLs and can be implanted during or after cataract surgery.

The Team

  • Nir Eliaz, CEO: 15 years of management and R&D experience in large corporate and medical device start-ups; former CEO and R&D manager ReLeaf Medical; B.Sc., biomechanical engineering
  • Prof. Ehud Assia, M.D., Co-Founder: Director, Ophthalmology Department, Meir Medical Center; professor, Tel Aviv University; medical director, Ein Tal Eye Center; reviewer and board member of ophthalmology journals; founder, Laboratory of Experimental Microsurgery, Meir Medical Center; former director, Department of Ophthalmology, Sackler School of Medicine of Tel Aviv University
  • Nir Betser, Co-Founder: 20 years’ experience in R&D and managing state-of-the-art technology projects; vast experience in business management; long career as business attorney; graduate of Talpiot (elite Israel Air Force program); LLB; B.Sc., physics and mathematics, Tel Aviv University

Status & Achievements

Founded: October 2013
Stage: Technology development
Investor: The Trendlines Group
IP: Patent applications in the United States and EU (National phase)

  • Advanced prototype
  • Animal study

In the media: IATI meets VisiDome: “Seeing near and far”

Background & Market

Over 20 million people worldwide undergo cataract surgery each year.

The surgery involves removing the eye’s cloudy natural lens and replacing it with an implanted artificial intraocular lens (IOL).

Today’s implanted monofocal IOLs typically provide clear distance vision only, making it difficult to focus on closer objects. As a result, even after undergoing surgery, people require glasses for sharp near and intermediate vision.

Premium multifocal and accommodating IOLs were developed to provide a full range of vision (near, intermediate, distance); yet, existing products do not meet the goal. Patients may still require glasses for reading or using the computer.

The $2.8 billion (2015) global IOL market is forecasted to reach $3.5 billion by 2018, with a CAGR of 6%. The United States is the largest market for IOLs, with revenues forecasted to reach $1.2 billion by 2018. Market leaders include Abbott Medical Optics, Alcon, Bausch and Lomb, Hoya, and Zeiss.

Media


CEO Nir Eliaz presents at a Trendlines event.


VisiDome's product animation

VisiDome's IOL

VisiDome's accomodative IOL restores vision at all distances.

Contact

Nir Eliaz, CEO
+972.52.551.3055
nir@visidome.com
www.visidome.com

VisiDome

Font Resize
Contrast